Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.

Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, Lam M, de Keizer B, Fischer HP, Kristiansen G.

Oncotarget. 2019 Jun 25;10(41):4149-4160. doi: 10.18632/oncotarget.27024. eCollection 2019 Jun 25.

PMID:
31289613
Free PMC Article
2.

Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers.

Kremer A, Kremer T, Kristiansen G, Tolkach Y.

BMC Urol. 2019 Jun 6;19(1):46. doi: 10.1186/s12894-019-0479-z.

3.

Cribriform and glomeruloid acinar adenocarcinoma of the prostate-an intratumoural intraductal carcinoma?

Tolkach Y, Kristiansen G.

Histopathology. 2019 May;74(6):804-808. doi: 10.1111/his.13821. No abstract available.

PMID:
31006895
4.

Apelin and apelin receptor expression in renal cell carcinoma.

Tolkach Y, Ellinger J, Kremer A, Esser L, Müller SC, Stephan C, Jung K, Toma M, Kristiansen G, Hauser S.

Br J Cancer. 2019 Mar;120(6):633-639. doi: 10.1038/s41416-019-0396-7. Epub 2019 Feb 20.

PMID:
30783205
5.

[22-Year-Old Man with Suspected Lung Cancer].

Biener L, Thomas D, Tolkach Y, Skowasch D.

Dtsch Med Wochenschr. 2019 Jan;144(1):13-14. doi: 10.1055/a-0740-0117. Epub 2019 Jan 2. German. No abstract available.

PMID:
30602181
6.

An overview of translational prostate cancer cohorts for prognostic and predictive studies.

Tolkach Y, Kristiansen G.

Histopathology. 2019 Jan;74(1):161-170. doi: 10.1111/his.13770. Review.

PMID:
30565297
7.

Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma.

Zhao C, Tolkach Y, Schmidt D, Toma M, Muders MH, Kristiansen G, Müller SC, Ellinger J.

World J Urol. 2018 Nov 28. doi: 10.1007/s00345-018-2575-1. [Epub ahead of print]

PMID:
30488095
8.

Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.

Müller T, Tolkach Y, Stahl D, Steiner S, Hauser S, Ellinger J, Rabien A, Ralla B, Jung K, Stephan C, Kristiansen G.

Clin Genitourin Cancer. 2019 Feb;17(1):e167-e175. doi: 10.1016/j.clgc.2018.10.008. Epub 2018 Oct 23.

PMID:
30448104
9.

tRNA-halves are prognostic biomarkers for patients with prostate cancer.

Zhao C, Tolkach Y, Schmidt D, Muders M, Kristiansen G, Müller SC, Ellinger J.

Urol Oncol. 2018 Nov;36(11):503.e1-503.e7. doi: 10.1016/j.urolonc.2018.08.003. Epub 2018 Sep 9.

PMID:
30209018
10.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

11.

YRNA expression in prostate cancer patients: diagnostic and prognostic implications.

Tolkach Y, Niehoff EM, Stahl AF, Zhao C, Kristiansen G, Müller SC, Ellinger J.

World J Urol. 2018 Jul;36(7):1073-1078. doi: 10.1007/s00345-018-2250-6. Epub 2018 Feb 28.

PMID:
29492585
12.

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.

Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G.

Breast Cancer Res Treat. 2018 Jun;169(3):447-455. doi: 10.1007/s10549-018-4717-y. Epub 2018 Feb 17.

PMID:
29455299
13.

Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.

Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, Müller SC, Ellinger J.

Clin Epigenetics. 2018 Jan 23;10:11. doi: 10.1186/s13148-018-0444-9. eCollection 2018.

14.

The Heterogeneity of Prostate Cancer: A Practical Approach.

Tolkach Y, Kristiansen G.

Pathobiology. 2018;85(1-2):108-116. doi: 10.1159/000477852. Epub 2018 Jan 31.

PMID:
29393241
15.
16.
17.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
18.

YRNA expression predicts survival in bladder cancer patients.

Tolkach Y, Stahl AF, Niehoff EM, Zhao C, Kristiansen G, Müller SC, Ellinger J.

BMC Cancer. 2017 Nov 10;17(1):749. doi: 10.1186/s12885-017-3746-y.

19.

Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression.

Bläsius FM, Meller S, Stephan C, Jung K, Ellinger J, Glocker MO, Thiesen HJ, Tolkach Y, Kristiansen G.

Oncotarget. 2017 Aug 24;8(43):75076-75086. doi: 10.18632/oncotarget.20507. eCollection 2017 Sep 26.

20.

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.

Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H.

Pathol Int. 2017 Dec;67(12):597-601. doi: 10.1111/pin.12594. Epub 2017 Oct 19.

PMID:
29047227
21.

High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall.

Tolkach Y, Ellinger J, Müller S, Kristiansen G.

Pathology. 2017 Oct;49(6):665-668. doi: 10.1016/j.pathol.2017.06.005. Epub 2017 Aug 19. No abstract available.

PMID:
28830691
22.

Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G.

J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.

PMID:
28827104
23.

5'-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma.

Zhao C, Tolkach Y, Schmidt D, Kristiansen G, Müller SC, Ellinger J.

J Urol. 2018 Feb;199(2):378-383. doi: 10.1016/j.juro.2017.07.082. Epub 2017 Jul 29.

PMID:
28765068
24.

Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma.

Brüggemann M, Gromes A, Poss M, Schmidt D, Klümper N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC, Ellinger J.

Transl Oncol. 2017 Aug;10(4):661-668. doi: 10.1016/j.tranon.2017.06.002. Epub 2017 Jun 30.

25.

[Molecular biomarkers and prognostic factors for prostate cancer].

Kretschmer A, Tolkach Y, Ellinger J, Kristiansen G.

Urologe A. 2017 Jul;56(7):933-944. doi: 10.1007/s00120-017-0418-0. Review. German.

PMID:
28573413
26.

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

Kristiansen I, Stephan C, Jung K, Dietel M, Rieger A, Tolkach Y, Kristiansen G.

Int J Mol Sci. 2017 May 29;18(6). pii: E1151. doi: 10.3390/ijms18061151.

27.

Development of a clinical algorithm for treating urethral strictures based on a large retrospective single-center cohort.

Tolkach Y, Herrmann T, Merseburger A, Burchardt M, Wolters M, Huusmann S, Kramer M, Kuczyk M, Imkamp F.

Version 2. F1000Res. 2016 Sep 26 [revised 2017 Jan 1];5:2378. doi: 10.12688/f1000research.9427.2. eCollection 2016.

28.

Adipophilin as prognostic biomarker in clear cell renal cell carcinoma.

Tolkach Y, Lüders C, Meller S, Jung K, Stephan C, Kristiansen G.

Oncotarget. 2017 Apr 25;8(17):28672-28682. doi: 10.18632/oncotarget.15639.

29.

Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.

Ellinger J, Poss M, Brüggemann M, Gromes A, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Clin Genitourin Cancer. 2017 Aug;15(4):e551-e562. doi: 10.1016/j.clgc.2016.11.010. Epub 2016 Dec 1.

PMID:
28063846
30.

[Pathogenesis of urological complications after radiation therapy].

Tolkach Y, Kristiansen G.

Urologe A. 2017 Mar;56(3):293-300. doi: 10.1007/s00120-016-0292-1. Review. German.

PMID:
28005154
31.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.

Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D, Kristiansen G.

J Mol Diagn. 2017 Jan;19(1):107-114. doi: 10.1016/j.jmoldx.2016.08.008. Epub 2016 Dec 8.

PMID:
27939865
32.

Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.

Tolkach Y, Eminaga O, Wötzel F, Huss S, Bettendorf O, Eltze E, Abbas M, Imkamp F, Semjonow A.

Prostate. 2017 Mar;77(4):396-405. doi: 10.1002/pros.23278. Epub 2016 Nov 16.

PMID:
27862105
33.

Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma.

Ellinger J, Gromes A, Poss M, Brüggemann M, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Oncotarget. 2016 Dec 27;7(52):86490-86499. doi: 10.18632/oncotarget.13275.

34.

Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.

Nosov A, Reva S, Petrov S, Mamijev E, Novikov R, Veliev E, Imkamp F, Tolkach Y, Moiseenko V.

Prostate. 2016 Nov;76(15):1345-52. doi: 10.1002/pros.23165. Epub 2016 Feb 11.

PMID:
26864707
35.

Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.

Tolkach Y, Merseburger A, Herrmann T, Kuczyk M, Serth J, Imkamp F.

Anticancer Res. 2015 Oct;35(10):5443-51.

PMID:
26408707
36.

A new technique of bladder neck reconstruction during radical prostatectomy in patients with prostate cancer.

Tolkach Y, Godin K, Petrov S, Schelin S, Imkamp F.

Int Braz J Urol. 2015 May-Jun;41(3):455-65. doi: 10.1590/S1677-5538.IBJU.2014.0341.

37.

Acceptance, Prevalence and Indications for Robot-Assisted Laparoscopy - Results of a Survey Among Urologists in Germany, Austria and Switzerland.

Imkamp F, Herrmann TR, Tolkach Y, Dziuba S, Stolzenburg JU, Rassweiler J, Sulser T, Zimmermann U, Merseburger AS, Kuczyk MA, Burchardt M.

Urol Int. 2015;95(3):336-45. doi: 10.1159/000430502. Epub 2015 Jul 8.

PMID:
26160360
38.

Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Tolkach Y, Imkamp F, Godin K, Van Poppel H.

Korean J Urol. 2015 Feb;56(2):90-8. doi: 10.4111/kju.2015.56.2.90. Epub 2015 Jan 30. Review.

39.

Case report: Heterotopic intrarenally located adrenocortical oncocytoma.

Godin K, Bang N, Tolkach Y.

F1000Res. 2014 Mar 17;3:73. doi: 10.12688/f1000research.3780.1. eCollection 2014.

40.

Initial experiences with the Hemopatch® as a hemostatic agent in zero-ischemia partial nephrectomy.

Imkamp F, Tolkach Y, Wolters M, Jutzi S, Kramer M, Herrmann T.

World J Urol. 2015 Oct;33(10):1527-34. doi: 10.1007/s00345-014-1404-4. Epub 2014 Sep 20.

PMID:
25239500
41.
42.

Spontaneous pelvic rupture as a result of renal colic in a patient with klinefelter syndrome.

Reva S, Tolkach Y.

Case Rep Urol. 2013;2013:374973. doi: 10.1155/2013/374973. Epub 2013 Mar 26.

43.

Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?

Tolkach Y, Joniau S, Van Poppel H.

BJU Int. 2013 Jun;111(7):1021-30. doi: 10.1111/j.1464-410X.2013.11796.x. Epub 2013 Feb 18. Review.

44.

Epithelioid hemangioendothelioma of the kidney treated with sunitinib.

Tolkach Y, Petrov S, Lerut E, Van Poppel H.

Onkologie. 2012;35(6):376-8. doi: 10.1159/000338944. Epub 2012 May 21.

PMID:
22722460
45.

Vesico-Acetabular Fistula and Urolithiasis in the Hip Joint Cavity due to Persistent Bladder Entrapment after Acetabular Fracture.

Tolkach Y, Gadjiev N, Korol V, Gonchar I.

Korean J Urol. 2011 Mar;52(3):221-4. doi: 10.4111/kju.2011.52.3.221. Epub 2011 Mar 18.

Supplemental Content

Loading ...
Support Center